The Transparency Council meeting 19/2023 on 15 May 2023

The agenda includes:

Preparation of an opinion on the appropriateness of including e-stethoscopes in the list of prescription medical devices in the population of children with asthma with exacerbations, including its more severe forms, for home use.

Preparation of positions on the evaluation of drugs:

• Forxiga (dapagliflozin), for the indication: treatment of adult patients diagnosed with chronic kidney disease with eGFR <60 ml/min/1.73m2 and with albuminuria or proteinuria and treatment with ACE-i/ARB-based therapy for no less than four weeks or with contraindications to these therapies,
• Forxiga (dapagliflozin) for the indication: chronic heart failure in adult patients with an ejection fraction LVEF>40%, left ventricular hypertrophy or left atrial enlargement and NT-proBNP levels ≥ 300 pg/ml (or ≥600 pg/ml in patients with atrial fibrillation or atrial flutter) and persistent NYHA class II – IV disease symptoms.

Preparation of opinions on draft health policy programmes of local government units:

• „Orthoptic diagnostic examination of children aged 5-8 in the Municipality of Piaseczno”,
• “Rehabilitation for the residents of the Municipality of Kamieniec Ząbkowicki for the period 2023-2025”.

Preparation of opinions on the inclusion in the reimbursement procedure of medicines containing the active substances:

1. carboplatin for the indications:

• malignant neoplasm of the oesophagus (C15);
• cervical part of the oesophagus (C15.0);
• thoracic part of the oesophagus (C15.1);
• abdominal part of the oesophagus (C15.2);
• upper third of the oesophagus (C15.3);
• middle third of the oesophagus (C15.4);
• lower third of the oesophagus (C15.5);
• lesion exceeding the limits of a single location within the oesophagus (C15.8);
• oesophagus, location not specified (C15.9).

     2. paclitaxelfor the indications:

• malignant neoplasm of the oesophagus (C15);
• cervical part of the oesophagus (C15.0);
• thoracic part of the oesophagus (C15.1);
• abdominal part of the oesophagus (C15.2);
• upper third of the oesophagus (C15.3);
• middle third of the oesophagus (C15.4);
• lower third of the oesophagus (C15.5);
• lesion exceeding the limits of a single location within the oesophagus (C15.8);
• oesophagus, location not specified (C15.9);
• malignant neoplasm of the anus and anal canal (C21);
• anus, location not specified (C21.0);
• anal canal;
• lesion exceeding the limits of a single location within the rectum, anus and anal canal (C21.8).

Preparation of opinions on the continued inclusion in the reimbursement procedure of medicines containing the active substances:

• Fentanyl for the indication: transient pain in children with cancer who are receiving opioid maintenance therapy as part of the treatment of chronic cancer pain and who have documented contraindications to other short-acting opioids or have been found to be ineffective on these drugs.
• Desmopressin for the indication: primary isolated bedwetting in patients between 5-6 years of age with normal urinary thickening capacity after documented failure of 1-month supportive and motivational management.